重组人血管内皮抑素联合化放疗治疗晚期恶性肿瘤的临床观察

目的:探讨重组人血管内皮抑素(recombinant human endostatin,rh-ES)联合化放疗治疗晚期恶性肿瘤的疗效及安全性。方法:回顾性分析我科2010年1月至2013年8月收治的27例晚期恶性肿瘤患者病例,27例患者均接受rh-ES联合化疗±放疗的综合治疗,rh-ES用药1周期后评价生活质量变化及不良反应,2周期后评价疗效。结果:23例可评价近期疗效的患者客观有效率30.4%,疾病控制率78.3%。18例非小细胞肺癌(non-small cell lung cancer,NSCLC)中位无进展生存期5.5月,中位总生存期12.0月,1年生存率50.0%,2年生存率28.6%。全组患者生活质量改善或稳定23例(85.2%),Ⅲ~Ⅳ度不良反应8例次。结论:Rh-ES联合化放疗治疗晚期恶性肿瘤的疗效及安全性良好,可改善或稳定患者生活质量。与其他单纯化疗研究结果比较,晚期NSCLC的中位无进展生存期及1年生存率较高,值得临床推广。

Clinical Observation of Recombinant Human Endostatin Combined with Chemoradiotherapy for Advanced Malignancies

Objective:To investigate the efficacy and safety of recombinant human endostatin (rh-ES) combined with chemotherapy (CT) or chemoradiotherapy (CRT) in treatment of advanced malignancies.Methods:27 cases of advanced malignancies in our department fromJanuary 2010 to August 2013 were retrospectively analyzed. All 27 patients were treated with Rh-ES combined with CT or CRT. The safety and changes of the quality of life were evaluated after one cycle after treatment,and the efficacy was evaluated after two cycles.Results:Among 23 evaluable cases, the objective response rate (ORR) was 30.4% and the disease control rate (DCR) was 78.3%. Among 18 cases of advanced non-small cell lung cancer (NSCLC), the median progression free survival (PFS) was 5.5 months, and the median overall survival (OS) was 12.0 months,1-year survival rate was 50.0%, and 2-year survival rate was 28.6%. For the quality of life (QOL) of these patients, 23 cases (85.2%) were improved or stable. The adverse reaction of G3/4 was present only 8 times.Conclusion:Rh-ES combined CT or CRT were effective and safety for advanced malignancies, and the quality of life could be improved or remained stable. Compared with other results of chemotherapy alone, the median PFS and 1-year survival rate in advanced NSCLC were higher, so it is worthy for further clinical application.